183 related articles for article (PubMed ID: 21882135)
1. [Biologicals first-line in chronic inflammatory bowel disease? No].
Herrlinger K; Stange EF
Dtsch Med Wochenschr; 2011 Sep; 136(36):1789. PubMed ID: 21882135
[No Abstract] [Full Text] [Related]
2. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
Danese S; Angelucci E
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
[TBL] [Abstract][Full Text] [Related]
3. Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses.
Marchetti M; Liberato NL
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):815-24. PubMed ID: 25262931
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
[No Abstract] [Full Text] [Related]
5. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
Hellström PM; Schmidt D; Karlén P
Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
[No Abstract] [Full Text] [Related]
6. [Biologicals in gastroenterology: TNF-blockers].
Scharl M; Rogler G
Dtsch Med Wochenschr; 2010 Nov; 135(45):2243-52. PubMed ID: 21046532
[TBL] [Abstract][Full Text] [Related]
7. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
Gearry RB; Irving PM
J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
[No Abstract] [Full Text] [Related]
8. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
Moum B
Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
[No Abstract] [Full Text] [Related]
9. [Better to start from top?].
MMW Fortschr Med; 2005 Oct; 147(42):8. PubMed ID: 16281774
[No Abstract] [Full Text] [Related]
10. Rheumatic fever in a patient receiving infliximab therapy for Crohn disease.
Abu-El-Haija M; Stasheff S; Atkins DL; Bishop WP
J Pediatr Gastroenterol Nutr; 2011 Mar; 52(3):360-1. PubMed ID: 21150656
[No Abstract] [Full Text] [Related]
11. [Treatment of Crohn's disease: step-up or top-down?].
Herrlinger K; Stange EF
Dtsch Med Wochenschr; 2010 Aug; 135(34-35):1694-8. PubMed ID: 20721847
[No Abstract] [Full Text] [Related]
12. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
Sorrentino D; Terrosu G; Vadalà S; Avellini C
Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
[No Abstract] [Full Text] [Related]
13. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
Rencz F; Péntek M; Bortlik M; Zagorowicz E; Hlavaty T; Śliwczyński A; Diculescu MM; Kupcinskas L; Gecse KB; Gulácsi L; Lakatos PL
World J Gastroenterol; 2015 Feb; 21(6):1728-37. PubMed ID: 25684937
[TBL] [Abstract][Full Text] [Related]
14. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease.
Desai AA; Marks DJ
Expert Rev Clin Immunol; 2010 Sep; 6(5):695-9. PubMed ID: 20828275
[No Abstract] [Full Text] [Related]
15. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
Meier J; Sturm A
Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
[No Abstract] [Full Text] [Related]
16. [Drug therapy of Crohn disease].
Niemelä S
Duodecim; 2001; 117(8):807-14. PubMed ID: 12116446
[No Abstract] [Full Text] [Related]
17. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
[TBL] [Abstract][Full Text] [Related]
18. [CED therapy with infliximab. Rapid and lasting remission - complete mucosal healing].
Wedekind S
MMW Fortschr Med; 2011 Dec; 153(48):54-5. PubMed ID: 22299262
[No Abstract] [Full Text] [Related]
19. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
Domènech E; López San Román A; Garcia-Planella E
Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
[No Abstract] [Full Text] [Related]
20. The cost-effectiveness of infliximab in Crohn's disease.
Smart C; Selinger CP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
